Bicycle Therapeutics Limited BCYC 深 沪
等待开盘 12-17 09:30:00 美东时间
7.31
-0.020
-0.27%
华盛通- 最 高7.405
- 今 开7.31
- 成交量 24.53万股
- 最 低 7.10
- 昨 收 7.33
- 总市值 5.07亿
- 52周最高 15.47
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 6.03
- 委 比 -98.02%
- 总股本 6930.65万
- 历史最高 62.075
- 量 比 1.10
- 振 幅 4.16%
- 历史最低 6.03
- 每 手 1
- 风险率 2.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bicycle Therapeutics Secures Long-Term Nuclear And Industry Partnerships To Support 212Pb Radiopharmaceutical Development And Commercial Supply
Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of
12-16 14:09
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On Bicycle Therapeutics with Hold Rating, Announces Price Target of $10
Truist Securities analyst Gregory Renza initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Hold rating and announces Price Target of $10.
11-25 01:54
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
RBC Capital Downgrades Bicycle Therapeutics to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Leonid Timashev downgrades Bicycle Therapeutics (NASDAQ:BCYC) from Outperform to Sector Perform and lowers the price target from $27 to $11.
10-31 17:51
Bicycle Therapeutics Q3 EPS $(0.85) Beats $(1.09) Estimate, Sales $11.734M Beat $7.333M Estimate
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.09) by 22.37 percent. This is a 14.86 percent decrease over losses of $(0.74) per share
10-30 19:44
Bicycle Therapeutics Expands Board with New Appointments
Bicycle Therapeutics ( ($BCYC) ) has provided an announcement. On September 8, ...
09-09 04:40
4 Analysts Assess Bicycle Therapeutics: What You Need To Know
In the last three months, 4 analysts have published ratings on Bicycle Therapeu...
08-13 03:00
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $44
Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $48 to $44.
08-11 21:06
